Peptide merchants are classified high-risk, which changes underwriting, reserves, and how fast an account can be closed. This is how approval decisions are actually made, why one MID is a single point of failure, and how to build processing redundancy before you need it.
Peptide brands are shut down by their payment processor at least as often as by their ad account, and the second failure is worse because it stops revenue instantly. Underwriters classify the category as high risk based on chargeback exposure and the claim risk visible on the website, which means site copy is part of the underwriting file. Aggregators are the common starting point and the common failure point, because their model is to remove risk categories in bulk rather than underwrite them individually; a dedicated merchant account is underwritten to your business and can be defended. Redundancy is the real answer: more than one merchant account, deliberately load-balanced, so a single underwriting decision cannot halt sales. Chargeback ratios, refund policy, fulfillment evidence, corporate structure and research-use-only labelling all feed the same evaluation. This is operational guidance, not legal or financial advice.
Risk classification is driven by chargeback probability, regulatory ambiguity, and product category rather than by your revenue quality. Research peptides combine an unsettled regulatory framing with a customer base that disputes readily, which puts the category in the same underwriting bucket as supplements, nutra, and other restricted verticals. The practical effect is higher rates, rolling reserves, and closer ongoing monitoring.
Aggregators place many merchants under one master account, so a single risky vertical threatens the whole portfolio. Their risk model is to remove first and review later, which is why aggregator accounts in this category are usually terminated without notice rather than negotiated. A dedicated merchant account underwritten specifically for your business is far harder to close abruptly.
Chargeback and refund history, the claims made on your live site, the visibility of refund and shipping policies, proof that you can fulfill what you sell, corporate structure and ownership documentation, and processing history if you have it. Site copy carries more weight than most founders expect — human-use or outcome claims on a research product will sink an application that is otherwise clean.
More than one, always. Running a single MID means one underwriting decision can stop all revenue on the same day. The standard structure is a primary account carrying most volume, at least one warmed secondary with live transactions, and a routing layer that can shift volume without a site change.
Assume held funds and a rolling reserve release schedule, so plan cash flow around receiving that balance later rather than immediately. Route volume to the secondary account, export the subscription and card-on-file data you are entitled to before access closes, and start the replacement application the same week. Preparing this before a shutdown is the entire difference between a bad week and an insolvent quarter.